OncoMatch/Clinical Trials/NCT05294055
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Is NCT05294055 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Etoposide and Cyclophosphamide for multiple myeloma.
Treatment: Etoposide · Cyclophosphamide · Mecapegfilgrastim, day 2 · Mecapegfilgrastim, day 5 — This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received:
Patients who had achieved at least partial response (PR)
Cannot have received: hematopoietic stem cell mobilization
Patients who had previously attempted hematopoietic stem cell mobilization
Cannot have received: bone marrow transplantation
Patients who had undergone previous bone marrow transplantation
Cannot have received: lenalidomide (lenalidomide)
Exception: more than 4 cycles or received within 4 weeks prior to mobilization chemotherapy
Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy
Cannot have received: fludarabine (fludarabine)
Patients who previously been treated with fludarabine
Cannot have received: melphalan (melphalan)
Patients who previously been treated with melphalan
Cannot have received: radiation therapy
Exception: plan to receive radiation within 30 days after transplantation or had received radiation therapy in the pelvis
Patients who plan to receive radiation within 30 days after transplantation; Patients who had received radiation therapy in the pelvis
Lab requirements
Blood counts
White blood cell count (WBC) <2.5×10^9/L; Absolute neutrophil count (ANC) <1.5×10^9/L; Platelets count (PLT) <80×10^9/L [excluded]
Kidney function
Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min [excluded]
Liver function
AST/ALT/Total bilirubin > 2.5 X ULN [excluded]
Cardiac function
angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable
Patients with angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable for hematopoietic stem cell mobilization or hematopoietic stem cell transplantation; White blood cell count(WBC)<2.5×10^9/L; Absolute neutrophil count(ANC)<1.5×10^9/L; Platelets count(PLT)<80×10^9/L; Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min; AST/ALT/Total bilirubin > 2.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05294055 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hematopoietic stem cell mobilization, bone marrow transplantation, lenalidomide disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages